Key information

🔎 Fund Overview

Summit Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Ivonescimab is a novel first-in-class programmed cell death protein 1 (PD-1) / vascular endothelial growth factor (VEGF) bispecific antibody. ivonescimab, as a single molecule, blocks PD-1 from binding to PD-L1 and PD-L2, and blocks VEGF from binding to VEGF receptors. Ivonescimab is being developed in China and Australia for multiple solid tumors. Its preclinical candidates include SMT-738, from the DDS-04 series for development in the fight against multidrug-resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections. It owns a genetics platform and a suite of software-based technologies (Discuva Platform), which facilitate the discovery and development of new mechanism antibiotics.